MX2015008898A - Metodos para el tratamiento de cancer pancreatico. - Google Patents
Metodos para el tratamiento de cancer pancreatico.Info
- Publication number
- MX2015008898A MX2015008898A MX2015008898A MX2015008898A MX2015008898A MX 2015008898 A MX2015008898 A MX 2015008898A MX 2015008898 A MX2015008898 A MX 2015008898A MX 2015008898 A MX2015008898 A MX 2015008898A MX 2015008898 A MX2015008898 A MX 2015008898A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- pancreatic cancer
- treating pancreatic
- treating
- taxane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
Abstract
En la presente se proporcionan métodos para el tratamiento de cáncer pancreático metastásico que comprende la administración de una composición que comprende nanopartículas que comprenden un taxano (por ejemplo, paclitaxel) y una proteína portadora en combinación con gemcitabina.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361751820P | 2013-01-11 | 2013-01-11 | |
US201361752355P | 2013-01-14 | 2013-01-14 | |
US13/794,480 US9511046B2 (en) | 2013-01-11 | 2013-03-11 | Methods of treating pancreatic cancer |
PCT/US2014/011145 WO2014110443A1 (en) | 2013-01-11 | 2014-01-10 | Methods of treating pancreatic cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015008898A true MX2015008898A (es) | 2015-10-14 |
Family
ID=51165317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015008898A MX2015008898A (es) | 2013-01-11 | 2014-01-10 | Metodos para el tratamiento de cancer pancreatico. |
Country Status (24)
Country | Link |
---|---|
US (3) | US9511046B2 (es) |
EP (1) | EP2943192B9 (es) |
JP (3) | JP6342918B2 (es) |
KR (1) | KR102205710B1 (es) |
CN (2) | CN105025893A (es) |
AU (1) | AU2013203699B2 (es) |
BR (1) | BR112015016681A8 (es) |
CA (1) | CA2897589C (es) |
CY (1) | CY1124273T1 (es) |
DK (1) | DK2943192T3 (es) |
ES (1) | ES2878145T3 (es) |
HK (1) | HK1216853A1 (es) |
HR (1) | HRP20211062T1 (es) |
HU (1) | HUE056612T2 (es) |
IL (2) | IL239739A0 (es) |
LT (1) | LT2943192T (es) |
MX (1) | MX2015008898A (es) |
NZ (2) | NZ630230A (es) |
PL (1) | PL2943192T3 (es) |
PT (1) | PT2943192T (es) |
RS (1) | RS62076B1 (es) |
SI (1) | SI2943192T1 (es) |
WO (1) | WO2014110443A1 (es) |
ZA (1) | ZA201504877B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1585548T1 (sl) | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Sestave in metode odmerjanja farmakoloških sredstev |
DK2301531T3 (en) | 2005-02-18 | 2018-07-30 | Abraxis Bioscience Llc | COMBINATIONS AND WAYS FOR ADMINISTRATING THERAPEUTIC SUBSTANCES AND COMBINATION THERAPY |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
RU2433818C2 (ru) | 2005-08-31 | 2011-11-20 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Композиции, включающие слаборастворимые в воде фармацевтические вещества и противомикробные вещества |
EP3470071A1 (en) | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
DK2155188T3 (da) * | 2007-06-01 | 2013-11-04 | Abraxis Bioscience Llc | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft |
SG175239A1 (en) | 2009-04-15 | 2011-11-28 | Abraxis Bioscience Llc | Prion-free nanoparticle compositions and methods |
PT2552438T (pt) | 2010-03-26 | 2016-07-07 | Abraxis Bioscience Llc | Métodos de tratamento de carcinoma hepatocelular |
LT2552415T (lt) | 2010-03-29 | 2016-12-27 | Abraxis Bioscience, Llc | Vėžio gydymo būdai |
EP2552439B1 (en) | 2010-03-29 | 2022-07-20 | Abraxis BioScience, LLC | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
NZ706745A (en) | 2010-06-04 | 2017-01-27 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
AU2011264590B2 (en) * | 2010-06-07 | 2016-12-15 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
CN103648521A (zh) | 2011-04-28 | 2014-03-19 | 阿布拉科斯生物科学有限公司 | 纳米颗粒组合物的血管内递送及其应用 |
BR112014014323A2 (pt) | 2011-12-14 | 2017-06-13 | Abraxis Bioscience Llc | uso de excipientes poliméricos para liofilização ou congelamento de partículas |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
CA2903548A1 (en) | 2013-03-14 | 2014-09-25 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
WO2016197100A1 (en) | 2015-06-04 | 2016-12-08 | Crititech, Inc. | Nozzle assembly and methods for use |
RS62743B1 (sr) | 2015-06-29 | 2022-01-31 | Abraxis Bioscience Llc | Nanočestice koje sadrže sirolimus i albumin za primenu u lečenju tumora epiteloidnih ćelija |
WO2017003908A1 (en) * | 2015-06-30 | 2017-01-05 | The Trustees Of Columbia University In The City Of New York | Talc-bound compositions and uses thereof |
WO2017176628A1 (en) | 2016-04-04 | 2017-10-12 | Crititech, Inc. | Methods for solid tumor treatment |
EP3595717A1 (en) * | 2017-03-17 | 2020-01-22 | Imclone, LLC | Combination therapy for pancreatic cancer |
CA3063420A1 (en) | 2017-06-09 | 2018-12-13 | Crititech, Inc. | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |
CN115919815A (zh) | 2017-06-14 | 2023-04-07 | 克里蒂泰克公司 | 治疗肺部疾病的方法 |
KR20200064112A (ko) | 2017-10-03 | 2020-06-05 | 크리티테크, 인크. | 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달 |
EP3768268A4 (en) | 2018-03-20 | 2022-02-23 | Abraxis BioScience, LLC | METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE |
GB201908352D0 (en) * | 2019-06-11 | 2019-07-24 | Innovation Ulster Ltd | Sonodynamic therapy |
AU2020375810A1 (en) | 2019-10-28 | 2022-05-12 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
WO2021156340A1 (en) * | 2020-02-04 | 2021-08-12 | Swedish Orphan Biovitrum Ab (Publ) | Pdac treatment regimen |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
DE69433723T3 (de) | 1993-02-22 | 2008-10-30 | Abraxis Bioscience, Inc., Los Angeles | Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen |
US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
US20070092563A1 (en) | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
PT1023050E (pt) | 1997-06-27 | 2013-12-04 | Abraxis Bioscience Llc | Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização |
EP1171117A4 (en) | 1999-04-22 | 2002-08-07 | American Bioscience Inc | LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS |
CA2684454A1 (en) | 1999-05-21 | 2000-11-18 | American Bioscience, Llc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
ITMI20020681A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
KR20140027554A (ko) | 2002-12-09 | 2014-03-06 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
SI1585548T1 (sl) | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Sestave in metode odmerjanja farmakoloških sredstev |
AU2012201568B2 (en) | 2005-02-18 | 2014-07-31 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
DK2301531T3 (en) | 2005-02-18 | 2018-07-30 | Abraxis Bioscience Llc | COMBINATIONS AND WAYS FOR ADMINISTRATING THERAPEUTIC SUBSTANCES AND COMBINATION THERAPY |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
AU2006242540A1 (en) | 2005-04-29 | 2006-11-09 | Kosan Biosciences Incorporated | Method of treating multiple myeloma using 17-AAG of 17-AG of a prodrug of either |
CN101291658B (zh) | 2005-08-31 | 2014-04-16 | 阿布拉科斯生物科学有限公司 | 用于制备稳定性增加的水难溶性药物的组合物和方法 |
RU2433818C2 (ru) | 2005-08-31 | 2011-11-20 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Композиции, включающие слаборастворимые в воде фармацевтические вещества и противомикробные вещества |
JP2007297339A (ja) * | 2006-04-29 | 2007-11-15 | Torii Yakuhin Kk | 癌を治療又は検査するための医薬 |
WO2008027055A1 (en) | 2006-08-31 | 2008-03-06 | Abraxis Bioscience, Llc | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
EP3470071A1 (en) | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
SI2131821T1 (sl) | 2007-03-07 | 2018-11-30 | Abraxis Bioscience, Llc | Nanodelci, ki zajemajo rapamicin in albumin kot sredstvo proti raku |
US20100166869A1 (en) | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
DK2155188T3 (da) | 2007-06-01 | 2013-11-04 | Abraxis Bioscience Llc | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft |
RU2010145529A (ru) | 2008-04-10 | 2012-05-20 | АБРАКСИС БАЙОСАЙЕНС ЭлЭлСи (US) | Композиции гидрофобных производных таксана и их применение |
MX2010011165A (es) | 2008-04-10 | 2011-02-22 | Abraxis Bioscience Llc | Composiciones de derivados de taxano hidrofobos y sus usos. |
AU2009234267B2 (en) * | 2008-04-11 | 2014-10-30 | Seagen Inc. | Detection and treatment of pancreatic, ovarian and other cancers |
ES2668837T3 (es) | 2008-12-11 | 2018-05-22 | Abraxis Bioscience, Llc | Terapia de combinación que incluye un taxano y un agente terapéutico adicional |
GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
MX2011009452A (es) | 2009-03-13 | 2011-11-29 | Abraxis Bioscience Llc | Terapia de combinacion con derivados tiocolchicina. |
JP2012523433A (ja) | 2009-04-10 | 2012-10-04 | アブラクシス バイオサイエンス, エルエルシー | ナノ粒子処方物およびその使用 |
SG175239A1 (en) | 2009-04-15 | 2011-11-28 | Abraxis Bioscience Llc | Prion-free nanoparticle compositions and methods |
WO2010138839A2 (en) * | 2009-05-28 | 2010-12-02 | Abraxis Bioscience, Llc | Use of 2 anti-sparc antibodies to predict response to chemotherapy |
SG10201609290PA (en) | 2009-08-25 | 2016-12-29 | Abraxis Bioscience Llc | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
JP2011079788A (ja) * | 2009-10-08 | 2011-04-21 | Oita Univ | 膵癌に対する選択的膵動脈制癌剤注入療法と全身化学療法との併用療法、およびそれに使用する膵癌治療薬 |
NZ601324A (en) * | 2010-01-05 | 2014-10-31 | Vascular Biogenics Ltd | Methods for use of a specific anti-angiogenic adenoviral agent |
PT2552438T (pt) | 2010-03-26 | 2016-07-07 | Abraxis Bioscience Llc | Métodos de tratamento de carcinoma hepatocelular |
LT2552415T (lt) | 2010-03-29 | 2016-12-27 | Abraxis Bioscience, Llc | Vėžio gydymo būdai |
EP2552439B1 (en) | 2010-03-29 | 2022-07-20 | Abraxis BioScience, LLC | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
WO2011121453A2 (en) | 2010-03-30 | 2011-10-06 | Clavis Pharma Asa | Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate |
EP2575803B1 (en) | 2010-06-02 | 2017-07-26 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
NZ706745A (en) | 2010-06-04 | 2017-01-27 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
AU2011264590B2 (en) | 2010-06-07 | 2016-12-15 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
CN103648521A (zh) | 2011-04-28 | 2014-03-19 | 阿布拉科斯生物科学有限公司 | 纳米颗粒组合物的血管内递送及其应用 |
BR112014014323A2 (pt) | 2011-12-14 | 2017-06-13 | Abraxis Bioscience Llc | uso de excipientes poliméricos para liofilização ou congelamento de partículas |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
KR102148551B1 (ko) | 2013-02-11 | 2020-08-26 | 아브락시스 바이오사이언스, 엘엘씨 | 흑색종을 치료하는 방법 |
EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
CN105209035A (zh) | 2013-03-13 | 2015-12-30 | 阿布拉科斯生物科学有限公司 | 治疗儿童实体瘤的方法 |
CA2903548A1 (en) | 2013-03-14 | 2014-09-25 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
WO2015157120A1 (en) | 2014-04-06 | 2015-10-15 | Abraxis Bioscience, Llc | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer |
WO2016141365A1 (en) | 2015-03-05 | 2016-09-09 | Abraxis Bioscience, Llc | Method for treating cancer based on level of glucocorticoid receptor |
RS62743B1 (sr) | 2015-06-29 | 2022-01-31 | Abraxis Bioscience Llc | Nanočestice koje sadrže sirolimus i albumin za primenu u lečenju tumora epiteloidnih ćelija |
IL256326B1 (en) | 2015-06-29 | 2024-05-01 | Abraxis Bioscience Llc | Biomarkers for nanoparticle preparations |
US20180153863A1 (en) | 2015-06-29 | 2018-06-07 | Abraxis Bioscience, Llc | Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy |
US20170181988A1 (en) | 2015-12-23 | 2017-06-29 | Cipla Limited | Methods for the treatment of bladder cancer |
-
2013
- 2013-03-11 US US13/794,480 patent/US9511046B2/en active Active
- 2013-04-11 AU AU2013203699A patent/AU2013203699B2/en active Active
-
2014
- 2014-01-10 WO PCT/US2014/011145 patent/WO2014110443A1/en active Application Filing
- 2014-01-10 HR HRP20211062TT patent/HRP20211062T1/hr unknown
- 2014-01-10 CA CA2897589A patent/CA2897589C/en active Active
- 2014-01-10 JP JP2015552834A patent/JP6342918B2/ja active Active
- 2014-01-10 CN CN201480013217.4A patent/CN105025893A/zh active Pending
- 2014-01-10 SI SI201431853T patent/SI2943192T1/sl unknown
- 2014-01-10 LT LTEP14737791.5T patent/LT2943192T/lt unknown
- 2014-01-10 NZ NZ630230A patent/NZ630230A/en unknown
- 2014-01-10 EP EP14737791.5A patent/EP2943192B9/en not_active Revoked
- 2014-01-10 DK DK14737791.5T patent/DK2943192T3/da active
- 2014-01-10 PL PL14737791T patent/PL2943192T3/pl unknown
- 2014-01-10 KR KR1020157021320A patent/KR102205710B1/ko active IP Right Review Request
- 2014-01-10 RS RS20210823A patent/RS62076B1/sr unknown
- 2014-01-10 MX MX2015008898A patent/MX2015008898A/es unknown
- 2014-01-10 CN CN201910067315.0A patent/CN109793728A/zh active Pending
- 2014-01-10 NZ NZ734971A patent/NZ734971A/en unknown
- 2014-01-10 ES ES14737791T patent/ES2878145T3/es active Active
- 2014-01-10 HU HUE14737791A patent/HUE056612T2/hu unknown
- 2014-01-10 BR BR112015016681A patent/BR112015016681A8/pt not_active Application Discontinuation
- 2014-01-10 PT PT147377915T patent/PT2943192T/pt unknown
-
2015
- 2015-07-01 IL IL239739A patent/IL239739A0/en unknown
- 2015-07-07 ZA ZA2015/04877A patent/ZA201504877B/en unknown
-
2016
- 2016-04-28 HK HK16104890.5A patent/HK1216853A1/zh unknown
- 2016-10-06 US US15/287,613 patent/US9855220B2/en active Active
-
2017
- 2017-11-21 US US15/820,022 patent/US10328031B2/en active Active
-
2018
- 2018-02-21 JP JP2018028611A patent/JP6697017B2/ja active Active
-
2019
- 2019-02-27 JP JP2019033910A patent/JP2019081790A/ja active Pending
-
2020
- 2020-02-26 IL IL272905A patent/IL272905A/en unknown
-
2021
- 2021-06-30 CY CY20211100585T patent/CY1124273T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015008898A (es) | Metodos para el tratamiento de cancer pancreatico. | |
MX2015010312A (es) | Metodos para tratamiento del melanoma. | |
PH12016502066A1 (en) | Methods of treating bladder cancer | |
PH12017550063A1 (en) | Combination therapies for treating cancers | |
EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
MX2016004678A (es) | Composiciones para el tratamiento del cancer. | |
TW201611847A (en) | Compounds and compositions for treating EGFR expressing tumors | |
ZA201602380B (en) | Cancer treatment with combination of plinabulin and taxane | |
WO2013177187A3 (en) | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents | |
NZ602382A (en) | Methods of treatment of hepatocellular carcinoma | |
MX2016000131A (es) | Nanoparticulas polimericas de docetaxel para el tratamiento de cancer. | |
MX2015007185A (es) | Uso de eribulina en el tratamiento de cancer de pecho. | |
MX2019010098A (es) | Antiandrogenos para el tratamiento del cancer de prostata resistente a la castracion no metastasico. | |
WO2016160621A3 (en) | Nk-92 cells in combination therapy with cancer drugs | |
PH12017501879A1 (en) | Methods for treating cancer | |
IL241823B (en) | Preparations containing novyi .c and their uses for the treatment of cancerous tumors | |
MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
MX2016015568A (es) | Derivados de nucleosidos para el tratamiento del cancer. | |
MX2015013021A (es) | 5-bromo-indirrubinas. | |
PH12014502109A1 (en) | Methods of treating cancer using aurora kinase inhibitors | |
IL250708A0 (en) | Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers | |
HK1215535A1 (zh) | 卡巴他賽及其治療轉移性前列腺癌的用途 | |
NZ725303A (en) | Anti-tumor agent containing taxane compound, and anti-tumor effect enhancer | |
UA88004U (ru) | Способ лечения рака пищевода | |
SG10201802995SA (en) | Cancer treatment with combination of plinabulin and taxane |